share_log

ECHOLIGHT ANNOUNCES NEW STUDY ON ECONOMIC IMPACT OF REMS IMPLEMENTATION IN CLINICAL PRACTICE

ECHOLIGHT ANNOUNCES NEW STUDY ON ECONOMIC IMPACT OF REMS IMPLEMENTATION IN CLINICAL PRACTICE

ECHOLIGHT 宣佈了一項關於 REMS 在臨牀實踐中實施經濟影響的新研究。
PR Newswire ·  02/11 15:00

HOUSTON, Feb. 11, 2025 /PRNewswire/ -- Echolight, a global leader in bone densitometry, has published a new study in JBMR Plus, the open-access journal of the American Society for Bone and Mineral Research (ASBMR) analyzing the economic impact of Radiofrequency Echographic Multi Spectrometry (REMS) for osteoporosis diagnosis in the U.S.

休斯頓,2025年2月11日 /PRNewswire/ -- Echolight,全球骨密度測量領域的領導者,已在美國骨骼與礦物研究學會(ASBMR)的開放獲取期刊JBMR Plus上發表了一項新研究,分析了射頻回聲多譜儀(REMS)在美國骨質疏鬆症診斷中的經濟影響。

With osteoporosis significantly underdiagnosed, REMS presents a non-ionizing, ultrasound-based alternative to DXA, demonstrating high accuracy and precision. The study evaluates the cost-effectiveness of REMS, finding that even a modest 5% increase in diagnosis and treatment could save 30,000 life-years, 43,500 QALYs, and prevent 100,000 fractures over a lifetime.

由於骨質疏鬆症顯著未被診斷,REMS提供了一種非離子化、基於超聲波的替代DXA的方法,顯示出高準確性和精確性。該研究評估了REMS的成本效益,發現即使只有5%的診斷和治療的適度增長,也可以在一生中節省30,000個生命年、43,500個QALY,並預防100,000次骨折。

With economic considerations playing an increasingly crucial role in healthcare decisions, the cost-effectiveness and economic impact (in terms of health outcomes and costs) of improved osteoporosis diagnosis using REMS followed by treatment in the United States has been evaluated and detailed in the newly released-paper entitled "Cost-effectiveness of radiofrequency echographic multi-spectrometry for the diagnosis of osteoporosis in the United States".

隨着經濟因素在醫療決策中扮演越來越重要的角色,針對美國利用REMS改善骨質疏鬆症診斷後進行治療的成本效益和經濟影響(包括健康結果和成本)進行了評估,並在新發佈的論文《美國骨質疏鬆症診斷的射頻回聲多譜測量成本效益》中進行了詳細說明。

Mike Yuja, Chief Commercial Officer and General Manager explained, "This study focused on US patients and is a great collaboration between research experts from Saudi Arabia, the United States, and the Netherlands. For the first time, the significant economic benefits of widespread REMS implementation in clinical practice in US have been analyzed and summarized."

首席商務官兼總經理Mike Yuja解釋說:「這項研究集中於美國患者,是沙特阿拉伯、美國和荷蘭研究專家之間的偉大合作。首次分析和總結了在美國臨牀實踐中廣泛實施REMS的顯著經濟利益。」

In conclusion, this study suggests that "REMS is a cost-effective strategy for the diagnosis and management of osteoporosis in US women, offering substantial potential economic benefits and improved health outcomes."

總之,這項研究表明:「REMS是一種在美國女性骨質疏鬆症診斷和管理中具有成本效益的策略,提供了可觀的潛在經濟利益和改善的健康結果。」

Echolight was established in Italy with a head office in Lecce, and in 2020 opened its offices in the United States. Since then, its sales network has grown to more than 40 distributors and several hundreds of satisfied customers across the world who have adopted the innovative REMS technology for assessing the bone condition of their patients.

Echolight成立於意大利,註冊總部位於萊切,並於2020年在美國開設了辦事處。從那時起,其銷售網絡已發展到超過40個分銷商和數百名滿意客戶,他們在全球範圍內採用了創新的REMS技術來評估患者的骨骼狀況。

Created as a spin-off of the Italian National Research Council, Echolight is at the forefront of medical innovation, introducing new cutting-edge solutions to contribute to human wellbeing. It has been awarded all the standard certificates: UNI CEI EN ISO 13485: 2016, Quality Management System UNI EN ISO 9001: 2015, CE mark, FDA clearance, and other major certificates worldwide for innovative solutions considered as the best practice in bone health for personalized medicine.

Echolight作爲意大利國家研究委員會的衍生公司,處於醫療創新的最前沿,推出了新的前沿解決方案,以促進人類的健康福祉。它獲得了所有標準證書:UNI CEI EN ISO 13485: 2016,質量管理體系UNI EN ISO 9001: 2015,CE標誌,FDA認證,以及世界範圍內其他主要證書,因其創新解決方案而被視爲個性化醫療的骨健康最佳實踐。

SOURCE Echolight Medical

資料來源 Echolight 醫療

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎?

440k+
440k+

Newsrooms &
新聞編輯室和

Influencers
意見領袖
9k+
9k+

Digital Media
數字媒體

Outlets
Outlets
270k+
270k+

Journalists
記者

Opted In
已選擇加入
GET STARTED
開始

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 332

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。